CurrentEndo
Get Weekly

CurrentEndo coverage · page 24 of 55

Diabetes, Obesity and Metabolism

Briefs 921–960 of 2,200 CurrentEndo has covered from this journal, newest publication first

Latest from Diabetes, Obesity and Metabolism

All coverage, newest first

  1. Diabetes Obes Metab

    Disrupted specialist outpatient services and alternative modes of service for patients with diabetes mellitus: A population‐based, retrospective cohort study in Hong Kong

    Cohort studyT2D & other

  2. Diabetes Obes Metab

    Glycaemic control after connected insulin pen initiation in people living with diabetes: Results from a real‐world setting

    Cohort studyTechnology

  3. Diabetes Obes Metab

    Cardiovascular and kidney outcomes of GLP ‐1 receptor agonists in adults with obesity: A target trial emulation study

    Research articleObesity

  4. Diabetes Obes Metab

    Impact of the era of diabetes onset in a national care system on the prevalence of retinopathy and microalbuminuria in people living with type 1 diabetes 15 years post‐diagnosis: A cross‐sectional, real‐world observational study

    Cross-sectional studyComplications

  5. Diabetes Obes Metab

    Efficacy and safety of once‐weekly subcutaneous semaglutide 2.4 mg for the management of overweight or obesity in Asian populations: A systematic review, meta‐analysis and meta‐regression of randomised trials

    Meta-analysisObesity

  6. Diabetes Obes Metab

    Efficacy and safety benefits of HR17031 , a fixed‐ratio combination of INS068 and noiiglutide, versus its components alone in Chinese patients with type 2 diabetes uncontrolled on oral antidiabetic drug(s): A phase 2, multicentre, open‐label, randomised, parallel three‐arm, treat‐to‐target trial

    Randomized controlled trialT2D & other

  7. Diabetes Obes Metab

    Social determinants of health and progression to cardio–renal–metabolic multimorbidity and mortality in people with prediabetes: A prospective cohort study

    Cohort studyT2D & other

  8. Diabetes Obes Metab

    Impact of glucagon‐like peptide‐1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes

    Cohort studyT2D & other

  9. Diabetes Obes Metab

    Combined liraglutide and metformin therapy in overweight or obese women with polycystic ovary syndrome: A systematic review and meta‐analysis

    Meta-analysisReproductive endocrine

  10. Diabetes Obes Metab

    Metrics that matter: Identifying endpoints for capturing the broad health impacts of prevention of obesity

    Research articleObesity

  11. Diabetes Obes Metab

    Efficacy and safety of oral semaglutide in Chinese participants with type 2 diabetes: Subgroup analyses by baseline characteristics in the PIONEER 11 and 12 randomised controlled trials

    Secondary analysisT2D & other

  12. Diabetes Obes Metab

    SGLT2 inhibitor therapy and lower incidence of iron deficiency anaemia in patients with type 2 diabetes: A retrospective cohort study from Germany

    Cohort studyT2D & other

  13. Diabetes Obes Metab

    Association between Chinese visceral adiposity index and heart failure in diabetic patients

    Cohort studyT2D & other

  14. Diabetes Obes Metab

    An MRI study of pancreatic atrophy in children with type 1 diabetes: Heterogeneity, disease duration effects, and progression prediction models

    Cohort studyT1D

  15. Diabetes Obes Metab

    Glycaemic responses to metformin monotherapy by SNP clusters in patients with type 2 diabetes

    Cohort studyT2D & other

  16. Diabetes Obes Metab

    Efficacy and safety of chiglitazar add‐on to metformin in type 2 diabetes mellitus ( RECAM study)

    Randomized controlled trialT2D & other

  17. Diabetes Obes Metab

    State‐level prevalence of chronic conditions co‐occurring with obesity among US adults

    Cross-sectional studyObesity

  18. Diabetes Obes Metab

    Cardiovascular disease risk estimates for primary prevention in the US prediabetes and diabetes population using the PREVENT equation

    Cross-sectional studyT2D & other

  19. Diabetes Obes Metab

    Mazdutide reduces body weight in adults with overweight or obesity: A high‐dose Phase 1 trial

    Randomized controlled trialObesity

  20. Diabetes Obes Metab

    Acidosis is associated with lower insulin sensitivity and incident type 2 diabetes in indigenous Americans: A prospective cohort study

    Cohort studyT2D & other

  21. Diabetes Obes Metab

    Comparison of subcutaneous, visceral, liver and muscle fat depots in relation to prevalent and incident diabetes

    Cohort studyT2D & other

  22. Diabetes Obes Metab

    Gender differences in the prescription of SGLT2 inhibitors in chronic kidney disease: A real‐world database study

    Cohort studyT2D & other

  23. Diabetes Obes Metab

    High‐intensity statin therapy is associated with reduced coronary inflammation on CT in patients with type 2 diabetes mellitus

    Cohort studyT2D & other

  24. Diabetes Obes Metab

    Understanding the clinical characteristics associated with health care costs and cost savings upon weight reduction in individuals with obesity or overweight

    Cohort studyObesity

  25. Diabetes Obes Metab

    Orforglipron, an oral non‐peptide glucagon‐like peptide‐1 receptor agonist, improves markers of β‐cell function and insulin sensitivity in type 2 diabetes

    Secondary analysisT2D & other

  26. Diabetes Obes Metab

    Diabetes screening in dialysis populations with a glucose challenge test and continuous glucose monitoring— DIGEST study

    Diagnostic or prognostic studyTechnology

  27. Diabetes Obes Metab

    Efficacy and safety of pioglitazone, empagliflozin and glimepiride as third‐line agents in patients with type 2 diabetes inadequately controlled with metformin and DPP ‐4 inhibitors: A multicentre, phase 4 randomized controlled trial

    Randomized controlled trialT2D & other

  28. Diabetes Obes Metab

    Adherence to app‐based dose guidance for once‐weekly insulin icodec in insulin‐naive individuals with type 2 diabetes: Post hoc analysis of ONWARDS 5

    Secondary analysisT2D & other

  29. Diabetes Obes Metab

    Comparative analysis on renal and cardiovascular outcomes of antidiabetic treatment in chronic kidney disease patients—A systematic review and network meta‐analysis

    Meta-analysisT2D & other

  30. Diabetes Obes Metab

    Metabolomic risk predictors of diabetic foot complications: A longitudinal observational study in type 1 diabetes

    Cohort studyT1D

  31. Diabetes Obes Metab

    Effectiveness of GLP ‐ 1RA according to different type 2 diabetes phenotypes: A retrospective study

    Cohort studyT2D & other

  32. Diabetes Obes Metab

    Ketosis and ketoacidosis in hospitalized patients receiving SGLT2 inhibitor therapy

    Cohort studyT2D & other

  33. Diabetes Obes Metab

    Long‐term effectiveness of iGlarLixi treatment in people with type 2 diabetes in the United States: The soli‐durability 24‐month observational study

    Cohort studyT2D & other

  34. Diabetes Obes Metab

    Prevalence and concordance of cardiometabolic risk markers and health behaviour among couples after a gestational diabetes mellitus‐affected pregnancy

    Cross-sectional studyDiabetes in pregnancy

  35. Diabetes Obes Metab

    GLY ‐200, an oral pharmacologic duodenal exclusion drug, resulted in positive effects on glucose, lipids and bodyweight in patients with type 2 diabetes: Results of a randomized, double‐blind placebo‐controlled trial

    Randomized controlled trialT2D & other

  36. Diabetes Obes Metab

    Combined GPR40 and GPR119 full agonism with K‐757 and K‐833 results in robust glucose lowering and modest weight loss in overweight/obese subjects with T2DM

    Randomized controlled trialT2D & other

  37. Diabetes Obes Metab

    Protective effect of metformin against dementia in patients with obesity: Results from a global federated health network analysis

    Cohort studyObesity

  38. Diabetes Obes Metab

    Digitally enhanced ketogenic diet versus low‐fat diet for cardio‐renal‐metabolic health in a predominantly Hispanic adult population with overweight or obesity: Pilot randomised clinical trial

    Randomized controlled trialObesity

  39. Diabetes Obes Metab

    Efficacy and safety of CT ‐868, a novel, fully biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double‐blind, randomized placebo controlled phase 2 trial

    Randomized controlled trialT2D & other

  40. Diabetes Obes Metab

    Real‐world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic

    Cohort studyObesity

All 2,200 Briefs in ExploreShowing Briefs 921–960 of 2,200, newest first